25-Apr-2014 - Evotec SE

Evotec receives first milestone in Roche biomarker collaboration

Evotec AG announced the successful achievement of a milestone in its biomarker alliance with Roche. The milestone was achieved on the decision by Roche to use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended phase I oncology trial.

This is the first minor milestone achieved under the collaboration and licence agreement between Evotec and Roche, signed in 2011, which is part of the m4 Munich Biotech Cluster Personalized Medicine and Targeted Therapies initiative funded by the German Federal Ministry of Education and Research. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programmes for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.

Dr Mario Polywka, Chief Operating Officer of Evotec AG, commented: "We are delighted with receiving this milestone and the first validation of our novel biomarker concept with Roche. I would like to thank everyone involved in the project to date for the fantastic science they have developed and for the hard work and determination to see it succeed in a clinical setting."

Facts, background information, dossiers
  • companion diagnostics
  • cancer therapy
More about Evotec
  • News

    Evotec to realign Discovery Chemistry Operations

    Evotec AG announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed at its Abingdon (UK) facility, answering to an increasing requirement to operate closer to the principal R&D laboratories of our major customers. All project work in ... more

    Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance

    Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets. Evotec will apply its proprietary and integrated fragment-based drug discovery platform ... more

    Evotec Signs High Throughput Screening Agreement with Active Biotech

    Evotec AG announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Evotec will use its expertise and technologies in assay developme ... more

More about Roche